Pembrolizumab, USFDA
Enfortumab vedotin-ejfv oo leh pembrolizumab waxa u ansixisay USFDA kansarka urothelial urothelial ee horumarsan ama metastatic
Feb 2024: Maamulka Cuntada iyo Dawooyinka ayaa dadajiyay nidaamka oggolaanshaha ee laba daawo, enfortumab vedotin-ejfv (Padcev, Astellas Pharma) iyo pembrolizumab (Keytruda, Merck). Daawooyinkan waxaa loogu talagalay in lagu daweeyo dadka deegaanka ..
BMS, Bristol Myers Squibb, immunotherapy, melanoma metastatic, nivolumab iyo relatlimab, nivolumab iyo relatlimab-rmbw, Opdualag, USFDA
Marka hore LAG-3-Blocking antibody isku darka, Opdualag™ (nivolumab iyo relatlimab-rmbw), waxa u ansixisay FDA bukaanada qaba melanoma aan la dabooli karin ama metastatic
Abriil 2022: Maamulka Cunnada iyo Dawooyinka ee Mareykanka (FDA) ayaa ansixiyay Opdualag (nivolumab iyo relatlimab-rmbw), cusub, fasalka koowaad-ku-jira qiyaas go'an oo isku darka nivolumab iyo relatlimab oo loo maamulo faleebo hal xidid xididka ah, f..
BMS, Breyanzi, CAR - T Daaweynta unugyada, GARGAARKA GARGAARKA, Daaweynta CART, USFDA
Breyanzi - Daaweynta cusub ee CAR T-Cell ee laga helo BMS
Julaay 2021: Breyanzi (Lisocabtagene maraleucel; liso-cel), novel CD19-directed chimeric antigen receptor (CAR) T unug ay samaysay Bristol Myers Squibb (BMS), waxaa ansixiyay Maamulka Cuntada iyo Dawooyinka ee Maraykanka (US.
KEYTRUDA, Merck, NCT02362594, Pembrolizumab, DIIWAAN, USFDA
Pembrolizumab waxaa ansixiyay FDA si loogu daaweeyo daawada 'melanoma'
Febraayo 15, 2019, pembrolizumab (KEYTRUDA, Merck) waxaa ansixiyay Maamulka Cuntada iyo Dawooyinka ee daawaynta adjuvant ee bukaannada qaba melanoma oo ay ku lug leeyihiin qanjidhada qanjidhada (s) ka dib dib-u-soo-celin buuxda. Oggolaanshaha
Ablynx, ADAMTS13, CABLIVI, caplacizumab-yhdp, FDA, daaweynta immunosuppressive, USFDA
Caplacizumab-yhdp waxaa ogolaaday FDA
Bishii Febraayo 6, 2019, iyadoo lala kaashanayo is-weydaarsiga plasma iyo daaweynta difaaca jirka, Maamulka Cuntada iyo Dawooyinka ayaa u oggolaaday caplacizumab-yhdp (CABLIVI, Ablynx NV) bukaanada qaangaarka ah ee helay thrombotic thrombocytopeni ..
CABOMETYX, Cabozantinib, Exelixis, FDA, HCC, kansarka hepatocellular, Sorafenib, USFDA
Cabozantinib waa FDA-loo oggolaaday kansarka 'hepatocellular carcinoma'
Janaayo 14, 2019, cabozantinib (CABOMETYX, Exelixis, Inc.) waxaa ansixiyay Maamulka Cuntada iyo Dawooyinka ee bukaanada qaba kansarka hepatocellular (HCC) kuwaas oo horay loogu daaweeyay sorafenib. Appr-ka..
Acalabrutunib, Avelumab, Daaweynta CART, Dabrafanib, Kymiah, Dawooyinka ugu dambeeyay, Midostaurin, Niraparib, Pembrolizumab, Tecartus, Tisagenlecleucel, Trametinib, USFDA
Daawooyinka ugu dambeeyay ee daaweynta kansarka
Julaay 2021: Eeg dawooyinkii ugu dambeeyay ee daawaynta kansarka. Sannad kasta, ka dib marka la eego tijaabooyinka iyo arrimo kale oo muhiim ah, USFDA waxay ansixisay daawooyinka, sidaas awgeed bukaannada kansarka waxay hadda rumaysan karaan in daawadu aad u dhowdahay. ..